Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease: Efficacy and Safety

Blood Purification

Volumn 41, Issue 1-3, 2016, Pages 166-170

  Bomback, Andrew S ^a  

^a Columbia University College of Physicians and Surg ^*  (United States)

Author keywords

Aldosterone; Eplerenone; Hyperkalemia; Spironolactone

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; MINERALOCORTICOID ANTAGONIST; SPIRONOLACTONE; EPLERENONE;

BLOOD PRESSURE REGULATION; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; END STAGE RENAL DISEASE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HEMODIALYSIS PATIENT; HUMAN; HYPERKALEMIA; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANALOGS AND DERIVATIVES; BLOOD PRESSURE; COMPLICATION; DISEASE COURSE; DRUG EFFECTS; HEART STROKE VOLUME; HEART VENTRICLE REMODELING; HEMODIALYSIS; KIDNEY FAILURE, CHRONIC; METABOLISM; PATHOLOGY; PATIENT SAFETY; RENAL INSUFFICIENCY, CHRONIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ALDOSTERONE; BLOOD PRESSURE; DISEASE PROGRESSION; HEART FAILURE; HUMANS; KIDNEY FAILURE, CHRONIC; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; SPIRONOLACTONE; STROKE VOLUME; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 84954423200     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000441262     Document Type: Conference Paper

References (46)

1. Greene EL, Kren S, Hostetter TH: Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996; 98: 1063-1068.
2. Rocha R, Chander PN, Zuckerman A, Stier CT Jr: Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999; 33(1 pt 2):232-237.
3. Rocha R, Stier CT Jr, Kifor I, et al: Aldosterone: A mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000; 141: 3871-3878.
4. Bomback AS, Rekhtman Y, Klemmer PJ, Canetta PA, Radhakrishnan J, Appel GB: Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy. J Am Soc Hypertens 2012; 6: 338-345.
5. Sato A, Hayashi K, Naruse M, Saruta T: Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41: 64-68.
6. Horita Y, Taura K, Taguchi T, Furusu A, Kohno S: Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy. Nephrology (Carlton) 2006; 11: 462-466.
7. Bomback AS, Klemmer PJ: The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007; 3: 486-492.
8. Struthers AD: Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail 1996; 2: 47-54.
9. Naruse M, Tanabe A, Sato A, et al: Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension 2002; 40: 28-33.
10. Lakkis J, Lu WX, Weir MR: RAAS escape: A real clinical entity that may be important in the progression of cardiovascular and renal disease. Curr Hypertens Rep 2003; 5: 408-417.
11. Schjoedt KJ, Andersen S, Rossing P, Tarnow L, Parving HH: Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 2004; 47: 1936-1939.
12. Pitt B: 'Escape' of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther 1995; 9: 145-149.
13. Pitt B, Zannad F, Remme WJ, et al: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 1999; 341: 709-717.
14. Pitt B, Remme W, Zannad F, et al: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321.
15. Zannad F, McMurray JJ, Krum H, et al: Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21.
16. Beygui F, Montalescot G, Vicaut E, et al: Aldosterone and long-term outcome after myocardial infarction: A substudy of the French nationwide observatoire sur la prise en charge hospitalière, l'Evolution à un an et les caRactéristiques de patients présentant un infArctus du myocarde avec ou sans onde Q (OPERA) study. Am Heart J 2009; 157: 680-687.
17. Cicoira M, Zanolla L, Franceschini L, et al: Relation of aldosterone 'escape' despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2002; 89: 403-407.
18. Berl T, Katz FH, Henrich WL, de Torrente A, Schrier RW: Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure. Kidney Int 1978; 14: 228-235.
19. Hené RJ, Boer P, Koomans HA, Mees EJ: Plasma aldosterone concentrations in chronic renal disease. Kidney Int 1982; 21: 98-101.
20. Reams GP, Bauer JH: Effect of enalapril in subjects with hypertension associated with moderate to severe renal dysfunction. Arch Intern Med 1986; 146: 2145-2148.
21. Bomback AS, Klemmer PJ: Mineralocorticoid receptor blockade in chronic kidney disease. Blood Purif 2012; 33: 119-124.
22. Bomback AS, Kshirsagar AV, Ferris ME, Klemmer PJ: Disordered aldosterone-volume relationship in end-stage kidney disease. J Renin Angiotensin Aldosterone Syst 2009; 10: 230-236.
23. Schrier RW, Masoumi A, Elhassan E: Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome. Clin J Am Soc Nephrol 2010; 5: 1132-1140.
24. Hung SC, Lin YP, Huang HL, Pu HF, Tarng DC: Aldosterone and mortality in hemodialysis patients: role of volume overload. PLoS One 2013; 8:e57511.
25. Bomback AS, Klemmer PJ: Interaction of aldosterone and extracellular volume in the pathogenesis of obesity-associated kidney disease: A narrative review. Am J Nephrol 2009; 30: 140-146.
26. Volk MJ, Bomback AS, Klemmer PJ: Mineralocorticoid receptor blockade in chronic kidney disease. Curr Hypertens Rep 2011; 13: 282-288.
27. Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ: Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: A systematic review. Am J Kidney Dis 2008; 51: 199-211.
28. Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF: Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev 2009; 3:CD007004.
29. Gross E, Rothstein M, Dombek S, Juknis HI: Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients. Am J Kidney Dis 2005; 46: 94-101.
30. Shavit L, Neykin D, Lifschitz M, Slotki I: Effect of eplerenone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric chronic hemodialysis patients-A pilot study. Clin Nephrol 2011; 76: 388-395.
31. Vardeny O, Wu DH, Desai A, et al: Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (randomized aldactone evaluation study). J Am Coll Cardiol 2012; 60: 2082-2089.
32. Edwards NC, Steeds RP, Stewart PM, Ferro CJ, Townend JN: Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: A randomized controlled trial. J Am Coll Cardiol 2009; 54: 505-512.
33. Sato A, Funder JW, Saruta T: Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis. Am J Hypertens 1999; 12(9 pt 1):867-873.
34. Steigerwalt S, Zafar A, Mesiha N, Gardin J, Provenzano R: Role of aldosterone in left ventricular hypertrophy among African-American patients with end-stage renal disease on hemodialysis. Am J Nephrol 2007; 27: 159-163.
35. Taheri S, Mortazavi M, Shahidi S, et al: Spironolactone in chronic hemodialysis patients improves cardiac function. Saudi J Kidney Dis Transpl 2009; 20: 392-397.
36. Taheri S, Mortazavi M, Pourmoghadas A, Seyrafian S, Alipour Z, Karimi S: A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis. Saudi J Kidney Dis Transpl 2012; 23: 507-512.
37. Fukuta H, Hayano J, Ishihara S, et al: Prognostic value of heart rate variability in patients with end-stage renal disease on chronic haemodialysis. Nephrol Dial Transplant 2003; 18: 318-325.
38. Flevari P, Kalogeropoulou S, Drakou A, et al: Spironolactone improves endothelial and cardiac autonomic function in non heart failure hemodialysis patients. J Hypertens 2013; 31: 1239-1244.
39. Nitta K, Akiba T, Nihei H: Aldosterone blockade and vascular calcification in hemodialysis patients. Am J Med 2003; 115: 250.
40. Vukusich A, Kunstmann S, Varela C, et al: A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients. Clin J Am Soc Nephrol 2010; 5: 1380-1387.
41. Chua D, Lo A, Lo C: Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: is it safe? Clin Cardiol 2010; 33: 604-608.
42. Baker WL, White WB: Safety of mineralocorticoid receptor antagonists in patients receiving hemodialysis. Ann Pharmacother 2012; 46: 889-894.
43. Rekhtman Y: Mineralocorticoid receptor-associated hypertension and target organ damage: clinical relevance for resistant hypertension in end stage renal disease. Curr Hypertens Rev 2012; 8: 267-275.
44. Hausmann MJ, Liel-Cohen N: Aldactone therapy in a peritoneal dialysis patient with decreased left ventricular function. Nephrol Dial Transplant 2002; 17: 2035-2036.
45. Matsumoto Y, Kageyama S, Yakushigawa T, et al: Long-term low-dose spironolactone therapy is safe in oligoanuric hemodialysis patients. Cardiology 2009; 114: 32-38.
46. Matsumoto Y, Mori Y, Kageyama S, et al: Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol 2014; 63: 528-536.